Current status and future directions of hepatocellular carcinoma-targeted nanoparticles and nanomedicine

References

• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. 2018;391(10127):1301–1314.
   Google Scholar
• Zamboni CG, Kozielski KL, Vaughan HJ, et al. Polymeric nanoparticles as cancer-specific DNA delivery vectors to human hepatocellular carcinoma. J Control Release. 2017;263:18–28.
   PubMed Web of Science ®Google Scholar
• Li LM, Bin HZ, Zhou ZX, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res. 2010;70(23):9798–9807. .
   PubMed Web of Science ®Google Scholar
• Yang N, Ekanem NR, Sakyi CA, et al. Hepatocellular carcinoma and microRNA: new perspectives on therapeutics and diagnostics. 2015:81:62–74.
   Google Scholar
• Jiang Y, Sun A, Zhao Y, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature. 2019;567(7747):257–261. .
   PubMed Web of Science ®Google Scholar
• Baig B, Halim SA, Farrukh A, Greish Y, Amin A. Current status of nanomaterial-based treatment for hepatocellular carcinoma, (2019) 116:108852
   Google Scholar
• Iranshahy M, Rezaee R, Karimi G. Hepatoprotective activity of metformin: A new mission for an old drug? 2019:5;850:1–7.
   Google Scholar
• Li C, Zhang W, Yang H, et al. Integrative analysis of dysregulated lncRNA-associated ceRNA network reveals potential lncRNA biomarkers for human hepatocellular carcinoma. PeerJ. 2020;2020:3.
   Google Scholar
• Hu WY, Wei HY, Li KM, et al. LINC00511 as a ceRNA promotes cell malignant behaviors and correlates with prognosis of hepatocellular carcinoma patients by modulating miR-195/EYA1 axis. Biomed Pharmacother. 2020;121. DOI:10.1016/j.biopha.2019.109642
   Web of Science ®Google Scholar
• Liu DH, Wang SL, Hua Y, et al. Five lncRNAs associated with the survival of hepatocellular carcinoma: a comprehensive study based on WGCNA and competing endogenous RNA network. Eur Rev Med Pharmacol Sci. 2020;24(14):7621–7633.
   PubMed Web of Science ®Google Scholar
• Rahman M, Beg S, Alharbi KS, et al. Implications of solid lipid nanoparticles of ganoderic acid for the treatment and management of hepatocellular carcinoma. J. Pharm. Innov 2020.
   Web of Science ®Google Scholar
• Pandey P, Rahman M, Bhatt PC, et al., Implication of nano-antioxidant therapy for treatment of hepatocellular carcinoma using PLGA nanoparticles of rutin. Nanomedicine. 13(8): 849–870. 2018. .
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. .
   PubMed Web of Science ®Google Scholar
• Subramani K, Elhissi A, Subbiah U, et al. Introduction to nanotechnology. In: Nanobiomaterials in Clinical Dentistry. 2019. p. 3–18.
   Google Scholar
• Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib. In: a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. 2008;7(10):3129–40.
   Google Scholar
• Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66(24):11851–11858. .
   PubMed Web of Science ®Google Scholar
• Xia H, Lee KW, Chen J, et al. Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib. Cell Death Discov. 2017;3(1):1. .
   Web of Science ®Google Scholar
• Sanchez F, Sobolev K. Nanotechnology in concrete - A review. 2010;24(11):2060–2071.
   Google Scholar
• Thakor AS, Gambhir SS. Nanooncology: the future of cancer diagnosis and therapy. CA Cancer J Clin. 2013;63(6):395–418.
   PubMed Web of Science ®Google Scholar
• Rizvi SAA, Saleh AM. Applications of nanoparticle systems in drug delivery technology. 2018;26(1): 64–70.
   Google Scholar
• Nasrollahzadeh M, Sajadi SM, Sajjadi M, et al. An Introduction to Nanotechnology. In: Interface Science and Technology. Vol. ume 28. 2019. p. 1–27.
   Google Scholar
• Pacelli S, Acosta F, Chakravarti AR, et al. Nanodiamond-based injectable hydrogel for sustained growth factor release: preparation, characterization and in vitro analysis. Acta Biomater. 2017;58:479–491.
   PubMed Web of Science ®Google Scholar
• Farajzadeh R, Pilehvar-Soltanahmadi Y, Dadashpour M, et al. Nano-encapsulated metformin-curcumin in PLGA/PEG inhibits synergistically growth and hTERT gene expression in human breast cancer cells. DOEArtif. Cells, Nanomedicine Biotechnol. 2018;46(5):917–925.
   PubMed Web of Science ®Google Scholar
• Zhu RX, Seto WK, Lai CL, et al. Epidemiology of hepatocellular carcinoma in the Asia-Pacific region. 2016;10(3):332–9.
   Google Scholar
• Lafaro KJ, Demirjian AN, Pawlik TM. Epidemiology of Hepatocellular Carcinoma. In: Surgical oncology clinics of north america. Vol. ume 24. 2015. p. 1–17.
   Google Scholar
• Omata M, Cheng AL, Kokudo N, et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. 2017;11(4):317–370.
   Google Scholar
• London WT, Petrick JL, McGlynn KA. Liver cancer. In: Schottenfeld and fraumeni cancer epidemiology and prevention, fourth edition. 2017. p. 635–660.
   Google Scholar
• Tang A, Hallouch O, Chernyak V, et al. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. 2018;43(1):13–25.
   Google Scholar
• Chen P-J, Lee P-H, Han K-H, et al. A phase III trial of muparfostat (PI-88) as adjuvant therapy in patients with hepatitis virus related hepatocellular carcinoma (HV-HCC) after resection. Ann Oncol. 2017;28(213):v. .
   Google Scholar
• Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35(9):2155–2166. .
   PubMed Web of Science ®Google Scholar
• Bennett H, Waser N, Johnston K, et al. A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan. 2015;9(3):378–90.
   Google Scholar
• Goh GBB, Chang PE, Tan CK. Changing epidemiology of hepatocellular carcinoma in Asia. 2015;29(6):919–28.
   Google Scholar
• Bagheri R, Sanaat Z, Zarghami N. Synergistic effect of free and nano-encapsulated chrysin-curcumin on inhibition of htert gene expression in SW480 colorectal cancer cell line. Drug Res. 2018;68(6):335–343. Stuttg. .
   Web of Science ®Google Scholar
• Mukherjee A, Sarkar S, Jana S, et al. Neuro-protective role of nanocapsulated curcumin against cerebral ischemia-reperfusion induced oxidative injury. Brain Res. 1704;164–173:2019.
   Google Scholar
• Shan D, Zhang C, Kalaba S, et al. Flexible biodegradable citrate-based polymeric step-index optical fiber. Biomaterials. 2017;143:142–148.
   PubMed Web of Science ®Google Scholar
• Willoughby JLS, Chan A, Sehgal A, et al. Evaluation of GalNAc-siRNA conjugate activity in pre-clinical animal models with reduced asialoglycoprotein receptor expression. Mol Ther. 2018;26(1):105–114. .
   PubMed Web of Science ®Google Scholar
• Witzigmann D, Quagliata L, Schenk SH, et al. Variable asialoglycoprotein receptor 1 expression in liver disease: implications for therapeutic intervention. Hepatol Res. 2016;46(7):686–696.
   PubMed Web of Science ®Google Scholar
• Gu D, Jin H, Jin G, et al. The asialoglycoprotein receptor suppresses the metastasis of hepatocellular carcinoma via LASS2-mediated inhibition of V-ATPase activity. Cancer Lett. 2016;379(1):107–116.
   PubMed Web of Science ®Google Scholar
• Oh HR, Jo HY, Park JS, et al. Galactosylated liposomes for targeted co-delivery of doxorubicin/vimentin sirna to hepatocellular carcinoma. Nanomaterials. 2016;6:8.
   Web of Science ®Google Scholar
• Sonoke S, Ueda T, Fujiwara K, et al. Galactose-modified cationic liposomes as a liver-targeting delivery system for small interfering RNA. Biol Pharm Bull. 2011;34(8):1338–1342.
   PubMed Web of Science ®Google Scholar
• Ni W, Li Z, Liu Z, et al. Dual-targeting nanoparticles: codelivery of Curcumin and 5-Fluorouracil for synergistic treatment of hepatocarcinoma. J Pharm Sci. 2019;108(3):1284–1295. .
   PubMed Web of Science ®Google Scholar
• Kamruzzaman Selim KM, Ha YS, Kim SJ, et al. Surface modification of magnetite nanoparticles using lactobionic acid and their interaction with hepatocytes. Biomaterials. 2007;28(4):710–716. .
   PubMed Web of Science ®Google Scholar
• Barker K, Rastogi SK, Dominguez J, et al. Biodegradable DNA-enabled poly(ethylene glycol) hydrogels prepared by copper-free click chemistry. J Biomater Sci Polym Ed. 2016;27(1):22–39.
   PubMed Web of Science ®Google Scholar
• Liu H, Wang H, Xu Y, et al. Lactobionic acid-modified dendrimer-entrapped gold nanoparticles for targeted computed tomography imaging of human hepatocellular carcinoma. Presented at. ACS Appl Mater Interfaces. 2014;6(9):6944–53.
   Web of Science ®Google Scholar
• Gao DY, Lin TT, Sung YC, et al. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer. Biomaterials. 2015;67:194–203.
   PubMed Web of Science ®Google Scholar
• Nasr M, Nafee N, Saad H, et al. Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice. Eur J Pharm Biopharm. 2014;88(1):216–225.
   PubMed Web of Science ®Google Scholar
• Bor G, Intan D, Mat A, et al. Nanomedicines for cancer therapy: current status, challenges and future prospects. Ther Deliv. 2019;10.2:113–132.
   Web of Science ®Google Scholar
• Wolfram J, Ferrari M. Clinical cancer nanomedicine. Nano Today. 2019;25:85–98.
   PubMed Web of Science ®Google Scholar
• Pan Z, Chen C, Long H, et al. Overexpression of GPC3 inhibits hepatocellular carcinoma cell proliferation and invasion through induction of apoptosis. Mol Med Rep. 2013;7(3):969–974. .
   PubMed Web of Science ®Google Scholar
• Xu L, Beckebaum S, Iacob S, et al. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. J Hepatol. 2014;60(3):590–598. .
   PubMed Web of Science ®Google Scholar
• Li J, Wang T, Jin B, et al. Diagnosis accuracy of serum glypican-3 level in patients with hepatocellular carcinoma: A systematic review with meta-analysis. 2018;33(4):353–363.
   Google Scholar
• Xie C, Tiede C, Zhang X, et al. Development of an Affimer-antibody combined immunological diagnosis kit for glypican-3. Sci Rep. 2017;7:1.
   PubMed Web of Science ®Google Scholar
• Sol C, Jang JH, Riener MO, et al. Serotonin promotes tumor growth in human hepatocellular cancer. Hepatology. 2010;51(4):1244–1254. .
   PubMed Web of Science ®Google Scholar
• Guri Y, Colombi M, Dazert E, et al. mTORC2 promotes tumorigenesis via lipid synthesis. Cancer Cell. 2017;32(6):807–823.e12. .
   PubMed Web of Science ®Google Scholar
• Cui L, Gao B, Cao Z, et al. Downregulation of B7-H4 in the MHCC97-H hepatocellular carcinoma cell line by arsenic trioxide. Mol Med Rep. 2016;13(3):2032–2038.
   PubMed Web of Science ®Google Scholar
• Liu P, Ge M, Hu J, et al. A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis. Hepatology. 2017;66(1):167–181. .
   PubMed Web of Science ®Google Scholar
• Li L, Jin R, Zhang X, et al. Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma. Hepatology. 2012;56(4):1380–1390. .
   PubMed Web of Science ®Google Scholar
• Ishiguro T, Sugimoto M, Kinoshita Y, et al. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res. 2008;68(23):9832–9838. .
   PubMed Web of Science ®Google Scholar
• Sadeghi S, Olevsky O, Hurvitz SA. Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine. 2014;7:329–38.
   Google Scholar
• Daniels TR, Bernabeu E, Rodríguez JA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. 2012;1820(3):291–317.
   Google Scholar
• Dai L, Cai R, Li M, et al. Dual-targeted cascade-responsive prodrug micelle system for tumor therapy in vivo. Chem Mater. 2017;29(16):6976–6992.
   Web of Science ®Google Scholar
• Zhang L, Gong F, Zhang F, et al. Targeted therapy for human hepatic carcinoma cells using folate-functionalized polymeric micelles loaded with superparamagnetic iron oxide and sorafenib in vitro. Int J Nanomedicine. 2013;8:1517–1524.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang X, Liao H, et al. Multifunctional shell–core nanoparticles for treatment of multidrug resistance hepatocellular carcinoma. Adv Funct Mater. 2018;28:14.
   Web of Science ®Google Scholar
• Wang K, Kievit FM, Sham JG, et al., Iron-Oxide-Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model. Small. 12(4): 477–487. 2016. .
   PubMed Web of Science ®Google Scholar
• Luria-Pérez R, Helguera G, Rodríguez JA. Anticuerpos que reconocen el receptor de transferrina en células tumorales. Bol. Med. Hosp. Infant. Mex. 2016;73(6):372–379.
   PubMedGoogle Scholar
• Wurz GT, Kao CJ, Degregorio MW. Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. 2016:28;4–31.
   Google Scholar
• Zhang X, Li J, Yan M. Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin. Drug Dev Ind Pharm. 2016;42(10):1590–1599. .
   PubMed Web of Science ®Google Scholar
• Malarvizhi GL, Retnakumari AP, Nair S, et al. Transferrin targeted core-shell nanomedicine for combinatorial delivery of doxorubicin and sorafenib against hepatocellular carcinoma. Nanomed Nanotechnol Biol Med. 2014;10(8):1649–1659.
   PubMed Web of Science ®Google Scholar
• Baker EN, Baker HM. Molecular structure. In: binding properties and dynamics of lactoferrin. 2005;62(22):2531–9.
   Google Scholar
• Golla K, Cherukuvada B, Ahmed F, et al. Anticancer activity of protein nanoparticle-based delivery of doxorubicin through intravenous administration in rats. PLoS One. 2012;7:12.
   Web of Science ®Google Scholar
• Lucock M. Folic acid: nutritional biochemistry, molecular biology, and role in disease processes. Mol Genet Metab. 2000;71(1–2):121–138.
   PubMed Web of Science ®Google Scholar
• Chen C, Ke J, Edward Zhou X, et al. Structural basis for molecular recognition of folic acid by folate receptors. Nature. 2013;500(7463):486–489. .
   PubMed Web of Science ®Google Scholar
• Cao N, Cheng D, Zou S, et al. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells. Biomaterials. 2011;32(8):2222–2232.
   PubMed Web of Science ®Google Scholar
• Ling D, Xia H, Park W, et al., PH-sensitive nanoformulated triptolide as a targeted therapeutic strategy for hepatocellular carcinoma. ACS Nano. 8(8): 8027–8039. 2014. .
   PubMed Web of Science ®Google Scholar
• De Luca LM. Retinoids and their receptors in differentiation, embryogenesis, and neoplasia. Faseb J. 1991;5(14):2924–2933.
   PubMed Web of Science ®Google Scholar
• Varshosaz J, Farzan M. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma. World J Gastroenterol. 2015;21(42):12022–12041. .
   PubMed Web of Science ®Google Scholar
• Cortes E, Lachowski D, Rice A, et al. Retinoic acid receptor-β is downregulated in hepatocellular carcinoma and cirrhosis and its expression inhibits myosin-driven activation and durotaxis in hepatic stellate cells. Hepatology. 2019;69(2):785–802.
   PubMed Web of Science ®Google Scholar
• Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer. 2001;1(3):181–193.
   PubMed Web of Science ®Google Scholar
• Varshosaz J, Hassanzadeh F, Aliabadi HS, et al. Cytotoxic effects of chitosan/retinoic acid/albumin targeted nanoparticles loaded with doxorubicin on human hepatoma cells. J. Isfahan Med. Sch. 2013;30(218):2206–2216.
   Google Scholar
• Zhou X, Zhang M, Yung B, et al. Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma. Int J Nanomedicine. 2012;7:5465–5474.
   PubMed Web of Science ®Google Scholar
• Niu C, Sun Q, Zhou J, et al. Folate-functionalized polymeric micelles based on biodegradable PEG-PDLLA as a hepatic carcinoma-targeting delivery system. Asian Pacific J Cancer Prev. 2011;12(8):1995–1999.
   PubMedGoogle Scholar
• Tseng HH, Chang JG, Hwang YH, et al. Expression of hepcidin and other iron-regulatory genes in human hepatocellular carcinoma and its clinical implications. J Cancer Res Clin Oncol. 2009;135(10):1413–1420.
   PubMed Web of Science ®Google Scholar
• Wilson B, Ozturk M, Takahashi H, et al. Cell-surface changes associated with transformation of human hepatocytes to the malignant phenotype. Proc Natl Acad Sci U S A. 1988;85(9):3140–3144. .
   PubMed Web of Science ®Google Scholar
• Takahashi H, Ozturk M, Wilson B, et al. In Vivo expression of two novel tumor‐associated antigens and their use in immunolocalization of human hepatocellular carcinoma. Hepatology. 1989;9(4):625–634. .
   PubMed Web of Science ®Google Scholar
• Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20(3):157–198.
   PubMed Web of Science ®Google Scholar
• Reynaert H, Rombouts K, Vandermonde A, et al. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut. 2004;53(8):1180–1189. .
   PubMed Web of Science ®Google Scholar
• Sun M, Wang Y, Shen J, et al. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo. Nanotechnology. 2010;21:47.
   Web of Science ®Google Scholar
• Jia WD, Xu GL, Wang W, et al. A somatostatin analogue, octreotide, inhibits the occurrence of second primary tumors and lung metastasis after resection of hepatocellular carcinoma in mice. Tohoku J Exp Med. 2009;218(2):155–160. .
   PubMed Web of Science ®Google Scholar
• Zhang L, Yu SU, Duan Z, et al. Treatment of liver cancer in mice by the intratumoral injection of an octreotide-based temperature-sensitive gel. Int J Mol Med. 2014;33(1):117–127. .
   PubMed Web of Science ®Google Scholar
• Verset G, Verslype C, Reynaert H, et al. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: A randomised multicentre phase III study. Br J Cancer. 2007;97(5):582–588. .
   PubMed Web of Science ®Google Scholar
• Marhaba R, Zöller M. CD44 in cancer progression: adhesion. In migration and growth regulation. 2004.
   Google Scholar
• Endo K, Terada T. Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol. 2000;32(1):78–84.
   PubMed Web of Science ®Google Scholar
• Xie Z, Choong PF, Poon LF, et al. Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion. Cancer Chemother Pharmacol. 2008;62(6):949–957. .
   PubMed Web of Science ®Google Scholar
• Wang L, Su W, Liu Z, et al. CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma. Biomaterials. 2012;33(20):5107–5114. .
   PubMed Web of Science ®Google Scholar
• Bottini M, Magrini A, Fadeel B, et al. Tackling chondrocyte hypertrophy with multifunctional nanoparticles. Gene Ther. 2016. DOI:10.1038/gt.2016.33
   PubMed Web of Science ®Google Scholar
• Ali Y, Alqudah A, Ahmad S, et al. Macromolecules as targeted drugs delivery vehicles: an overview. Des. Monomers Polym. 2019;22(1):91–97.
   PubMed Web of Science ®Google Scholar
• Methachan B, Polymer-Based TK. Materials in Cancer Treatment: from Therapeutic Carrier and Ultrasound Contrast Agent to Theranostic Applications. 2017;43(1):69–82.
   Google Scholar
• Li M, Zhang W, Wang B, et al. Ligand-based targeted therapy: A novel strategy for hepatocellular carcinoma. 2016;11: 5645–5669.
   Google Scholar
• Yameen B, Il CW, Vilos C, et al. Insight into nanoparticle cellular uptake and intracellular targeting. 2014;28;190:485–99.
   Google Scholar
• Upponi JR, Torchilin VP. Passive vs. Active Targeting: an Update of the EPR Role in Drug Delivery to Tumors. 2014;(197):3–53.
   Google Scholar
• Masood F. Polymeric nanoparticles for targeted drug delivery system for cancer therapy. 2016;60:569–578.
   Google Scholar
• Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. 2010;75(1):1–18.
   Google Scholar
• Dutta R, Kumar V, Peng Y, et al. Pharmacokinetics and Biodistribution of GDC-0449 loaded micelles in normal and liver fibrotic mice. Pharm Res. 2017. DOI:10.1007/s11095-016-2081-3
   PubMed Web of Science ®Google Scholar
• Zhang HT, Sun J, Yan Y, et al. Encapsulated microRNA by gemcitabine prodrug for cancer treatment. J Control Release. 2019. DOI:10.1016/j.jconrel.2019.11.010.
   Web of Science ®Google Scholar
• Zhang J, Zhang M, Ji J, et al. Glycyrrhetinic acid-mediated polymeric drug delivery targeting the acidic microenvironment of hepatocellular carcinoma. Pharm Res. 2015;32(10):3376–3390. .
   PubMed Web of Science ®Google Scholar
• Zhang J, Zheng Y, Xie X, et al. Cleavable multifunctional targeting mixed micelles with sequential ph-triggered tat peptide activation for improved antihepatocellular carcinoma efficacy. Mol Pharm. 2017;14(11):3644–3659. .
   PubMed Web of Science ®Google Scholar
• Negishi M, Irie A, Nagata N, et al. Specific binding of glycyrrhetinic acid to the rat liver membrane. BBA - Biomembr. 1991;1066(1):77–82.
   PubMed Web of Science ®Google Scholar
• Devulapally R, Foygel K, Sekar TV, et al. Nanoparticles for Hepatocellular Carcinoma Therapy. ACS Appl Mater Interfaces. 2016;8(49):33412–33422.
   PubMed Web of Science ®Google Scholar
• Chowdhury SM, Lee T, Bachawal SV, et al. Longitudinal assessment of ultrasound-guided complementary microRNA therapy of hepatocellular carcinoma. J Control Release. 2018;281:19–28.
   PubMed Web of Science ®Google Scholar
• Usmani A, Mishra A, Ahmad M. Nanomedicines: a theranostic approach for hepatocellular carcinoma. 2018;46(4):680–690.
   Google Scholar
• Kumar V, Bhatt PC, Rahman M, et al. Fabrication, optimization, and characterization of umbelliferone β-D-galactopyranoside-loaded PLGA nanoparticles in treatment of hepatocellular carcinoma: in vitro and in vivo studies. Int J Nanomedicine. 2017;12:6747–6758.
   PubMed Web of Science ®Google Scholar
• Jain NK, Jain SK. Development and in vitro characterization of galactosylated low molecular weight chitosan nanoparticles bearing doxorubicin. AAPS PharmSciTech. 2010;11(2):686–697. .
   PubMed Web of Science ®Google Scholar
• Bernier B. The production of polysaccharides by fungi active in the decomposition of wood and forest litter Can. BolJ. Microbiol. 1958;4(3):195–204.
   Web of Science ®Google Scholar
• Swierczewska M, Han HS, Kim K, et al. Polysaccharide-based nanoparticles for theranostic nanomedicine. 2016;99(Pt A):70–84.
   Google Scholar
• Li H, Sun Y, Liang J, et al. PH-Sensitive pullulan-DOX conjugate nanoparticles for co-loading PDTC to suppress growth and chemoresistance of hepatocellular carcinoma. J Mater Chem B. 2015;3(41):8070–8078.
   PubMed Web of Science ®Google Scholar
• Sui J, Cui Y, Cai H, et al. Synergistic chemotherapeutic effect of sorafenib-loaded pullulan-Dox conjugate nanoparticles against murine breast carcinoma. Nanoscale. 2017;9(8):2755–2767. .
   PubMed Web of Science ®Google Scholar
• Chittasupho C, Jaturanpinyo M, Mangmool S. Pectin nanoparticle enhances cytotoxicity of methotrexate against hepG2 cells. Drug Deliv. 2013;20(1):1–9.
   PubMed Web of Science ®Google Scholar
• Gurunathan S, Park JH, Han JW, et al. Comparative assessment of the apoptotic potential of silver nanoparticles synthesized by Bacillus tequilensis and Calocybe indica in MDA-MB-231 human breast cancer cells: targeting p53 for anticancer therapy. Int J Nanomedicine. 2015;10:4203–4223.
   PubMed Web of Science ®Google Scholar
• Raoof M, Corr SJ, Zhu C, et al. Gold nanoparticles and radiofrequency in experimental models for hepatocellular carcinoma. Nanomed Nanotechnol Biol Med. 2014;10(6):1121–1130. .
   PubMed Web of Science ®Google Scholar
• Zhang Q, Iwakuma N, Sharma P, et al. Gold nanoparticles as a contrast agent for invivo tumor imaging with photoacoustic tomography. Nanotechnology. 2009;20:39.
   Web of Science ®Google Scholar
• Kang JH, Toita R, Murata M. Liver cell-targeted delivery of therapeutic molecules. 2016;36(1):132–43.
   Google Scholar
• Soenen SJH, Brisson AR, Jonckheere E, et al. The labeling of cationic iron oxide nanoparticle-resistant hepatocellular carcinoma cells using targeted magnetoliposomes. Biomaterials. 2011;32(6):1748–1758. .
   PubMed Web of Science ®Google Scholar
• Singh D, Singh M, Yadav E, et al. Amelioration of diethylnitrosamine (DEN)-induced hepatocellular carcinogenesis in animal models via knockdown oxidative stress and proinflammatory markers by Madhuca longifolia embedded silver nanoparticles. RSC Adv. 2018;8(13):6940–6953. .
   PubMed Web of Science ®Google Scholar
• Faedmaleki F, Shirazi FH, Salarian AA, et al. Toxicity effect of silver nanoparticles on mice liver primary cell culture and HepG2 cell line. 2014;13(1):235–242. Iran. J. Pharm. Res.
   PubMed Web of Science ®Google Scholar
• El-Kharrag R, Amin A, Hisaindee S, et al. Development of a therapeutic model of precancerous liver using crocin-coated magnetite nanoparticles. Int J Oncol. 2017;50(1):212–222.
   PubMed Web of Science ®Google Scholar
• Meijer E, Kromhout H, Heederik D. Respiratory effects of exposure to low levels of concrete dust containing crystalline silica. Am J Ind Med. 2001;40(2):133–140.
   PubMed Web of Science ®Google Scholar
• Kim IY, Joachim E, Choi H, et al. Toxicity of silica nanoparticles depends on size, dose, and cell type. Nanomed Nanotechnol Biol Med. 2015;11(6):1407–1416.
   PubMed Web of Science ®Google Scholar
• Brinker CJ, Carnes EC, Ashley CE, et al. Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same. DOE Patents. 2017.
   Google Scholar
• Patra HK, Dasgupta AK. Cancer cell response to nanoparticles: criticality and optimality. Nanomed Nanotechnol Biol Med. 2012;8(6):842–852.
   PubMed Web of Science ®Google Scholar
• van der Meel R, Chen S, Zaifman J, et al. Modular lipid nanoparticle platform technology for siRNA and lipophilic prodrug delivery. bioRxiv. 2020. https://doi.org/10.1101/2020.01.16.907394
   Google Scholar
• Hoy SM. Patisiran: first Global Approval. Drugs. 2018;78(15):1625–1631.
   PubMed Web of Science ®Google Scholar
• Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Presented at. Adv Drug Deliv Rev. 2002;54(Suppl_1):S131–55.
   PubMed Web of Science ®Google Scholar
• Doktorovová S, Santos DL, Costa I, et al. Cationic solid lipid nanoparticles interfere with the activity of antioxidant enzymes in hepatocellular carcinoma cells. Int J Pharm. 2014;471(1–2):18–27.
   PubMed Web of Science ®Google Scholar
• Rahman M, Al-Ghamdi SA, Alharbi KS, et al. Ganoderic acid loaded nano-lipidic carriers improvise treatment of hepatocellular carcinoma. Drug Deliv. 2019;26(1):782–793. .
   PubMed Web of Science ®Google Scholar
• Pandita A, Pharmacosomes SP. An emerging novel vesicular drug delivery system for poorly soluble synthetic and herbal drugs. ISRN Pharm. 2013;1–10:2013.
   Google Scholar
• Bulbake U, Doppalapudi S, Kommineni N, et al. Liposomal formulations in clinical use: an updated review. 2017;9(2):12.
   Google Scholar
• Zhang X, Ng HLH, Lu A, et al. Drug delivery system targeting advanced hepatocellular carcinoma: current and future. 2016;12(4):853–869.
   Google Scholar
• Comfort KK, Maurer EI, Braydich-Stolle LK, et al. Interference of silver, gold, and iron oxide nanoparticles on epidermal growth factor signal transduction in epithelial cells. ACS Nano. 2011;5(12):10000–10008.
   PubMed Web of Science ®Google Scholar
• Salem DS, Sliem MA, El-Sesy M, et al. Improved chemo-photothermal therapy of hepatocellular carcinoma using chitosan-coated gold nanoparticles. J Photochem Photobiol B Biol. 2018;182:92–99.
   PubMed Web of Science ®Google Scholar
• Dar MA, Ingle A, Rai M. Enhanced antimicrobial activity of silver nanoparticles synthesized by Cryphonectria sp. evaluated singly and in combination with antibiotics. Nanomed Nanotechnol Biol Med. 2013;9(1):105–110.
   PubMed Web of Science ®Google Scholar
• van der Meel R, et al. Smart cancer nanomedicine. Nat Nanotechnol. 2019;14.11:1007–1017.
   Web of Science ®Google Scholar
• Zhao Y, Zhang Y, Mehdiabad MV, et al. Enhanced anti-tumor effect of liposomal Fasudil on hepatocellular carcinoma in vitro and in vivo. PLoS One. 2019;14(10):e0223232.
   Web of Science ®Google Scholar
• Cheng Y, Zhao P, Wu S, et al. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma. Int J Pharm. 2018. DOI:10.1016/j.ijpharm.2018.05.007.
   Web of Science ®Google Scholar
• Hann IM, Prentice HG. Lipid-based amphotericin B: A review of the last 10 years of use. 2001;17(3):161–9.
   Google Scholar
• Miller AD. Lipid-based nanoparticles in cancer diagnosis and therapy. J Drug Deliv. 2013;1–9:2013.
   Google Scholar
• Lombardi G, Zustovich F, Farinati F, et al. Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study. Cancer. 2011;117(1):125–133. .
   PubMed Web of Science ®Google Scholar
• Needham D, Ponce A. Nanoscale drug delivery vehicles for solid tumors: a new paradigm for localized drug delivery using temperature sensitive liposomes. In: Nanotechnology for Cancer Therapy. 2019. p. 677–719.
   Google Scholar
• Rahman A, Kessler A, More N, et al. Liposomal protection of adriamycin-induced cardiotoxicity in mice. Cancer Res. 1980;40(5):1532–1537.
   PubMed Web of Science ®Google Scholar
• Mohamed NK, Hamad MA, Hafez MZE, et al. Nanomedicine in management of hepatocellular carcinoma: challenges and opportunities. 2017;140(71):1475–1484.
   Google Scholar
• Wicki A, Witzigmann D, Balasubramanian V, et al. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. 2015;200:138–57.
   Google Scholar
• Rosenblum D, Joshi N, Tao W, et al. Progress and challenges towards targeted delivery of cancer therapeutics. 2018;9(1):1410.
   Google Scholar
• Shi J, Kantoff PW, Wooster R, et al. Cancer nanomedicine: progress, challenges and opportunities. 2017;17(1):20–37.
   Google Scholar
• Naahidi S, Jafari M, Edalat F, et al. Biocompatibility of engineered nanoparticles for drug delivery. 2013;166(2):182–94.
   Google Scholar
• Gref R, Minamitake Y, Peracchia MT, et al. Biodegradable long-circulating polymeric nanospheres. Science. 1994;(80-263)(5153):1600–1603.
   Web of Science ®Google Scholar
• Bahadar H, Maqbool F, Niaz K, et al. Toxicity of nanoparticles and an overview of current experimental models. 2016;20(1):1–11.
   Google Scholar
• Divya K, Jisha MS. Chitosan nanoparticles preparation and applications. 2018;16:101–112.
   Google Scholar
• Eftekhari A, Dizaj SM, Chodari L, et al. The promising future of nano-antioxidant therapy against environmental pollutants induced-toxicities. 2018;103:1018–1027.
   Google Scholar